Volume 16 • Issue 1 • PP: 75-85 • 2025
Leveraging Variational Autoencoder with Hippopotamus Optimizer-Based Dimensionality Reduction Model for Attention Deficit Hyperactivity Disorder Diagnosis Data
View PDF Abstract
Adverse Drug Reactions (ADRs) are very hazardous to patients. Thus, the detection of ADR intends to automatically distinguish, which is an intensive study for public health monitoring functions. Detecting ADRs is the most significant information to determine the patient’s opinion on some drugs. As patients can experience projected and occasionally unpredicted negative results from taking some drugs, late detection of ADRs may place life-threatening dangers to patients; posing significant financial, social, and legal consequences to the regulatory agencies and manufacturing companies. The usage of medical data, like states and electronic health records (EHR), became normal in offering a richer understanding of health services and assisting ADR analysis. Developments in deep learning (DL) and machine learning (ML) have made several analytic models have the potential to apply higher-dimensional data to predict adverse effects. In this study, we present a Hippopotamus Optimizer-Based Feature Selection for Adverse Drug Reaction Detection Using a Variational Autoencoder (HOFS-ADRDVAE) model. The main intention of the HOFS-ADRDVAE model is to provide an automatic system for the detection of ADR using state-of-the-art techniques. Initially, the data normalization stage employs min-max normalization for converting input data into a beneficial format. In addition, the feature selection process has been executed by the hippopotamus optimization (HO) algorithm. Besides, the proposed HOFS-ADRDVAE model designs a variational autoencoder (VAE) technique for the classification procedure. At last, the Hunger Games search (HGS) algorithm-based hyperparameter selection process is executed to optimize the classification results of the VAE system. A wide-ranging experiment was implemented to point out the performance of the HOFS-ADRDVAE method. The experimental outcomes specified that the HOFS-ADRDVAE model emphasized improvement over another existing method.
Keywords
References
[1] C. S. Wang, P. J. Lin, C. L. Cheng, S. H. Tai, Y. H. Kao Yang, and J. H. Chiang, “Detecting potential adverse drug reactions using a deep neural network model,” J. Med. Internet Res., vol. 21, no. 2, p. e11016, 2019.
[2] A. A. Pandit and S. A. Dubey, “A comprehensive review of Adverse Drug Reactions (ADRs) Detection and Prediction Models,” in Proc. 13th Int. Conf. Comput. Intell. Commun. Netw. (CICN), Sep. 2021, pp. 123–127.
[3] Z. Rezaei, H. Ebrahimpour-Komleh, B. Eslami, R. Chavoshinejad, and M. Totonchi, “Adverse drug reaction detection in social media by deep learning methods,” Cell J. (Yakhteh), vol. 22, no. 3, p. 319, 2019.
[4] B. Fan, W. Fan, and C. Smith, “Adverse drug event detection and extraction from open data: A deep learning approach,” Inf. Process. Manag., vol. 57, no. 1, p. 102131, 2020.
[5] H. Khalil and C. Huang, “Adverse drug reactions in primary care: a scoping review,” BMC Health Serv. Res., vol. 20, pp. 1–13, 2020.
[6] O. Choudhury et al., “Predicting adverse drug reactions on distributed health data using federated learning,” in AMIA Annu. Symp. Proc., vol. 2019, p. 313, Mar. 2020.
[7] R. Prasad, A. Singh, and N. Gupta, “Adverse drug reactions in tuberculosis and management,” Indian J. Tuberc., vol. 66, no. 4, pp. 520–532, 2019.
[8] F. Schifano, S. Chiappini, J. M. Corkery, and A. Guirguis, “An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions,” Int. J. Neuropsychopharmacol., vol. 22, no. 4, pp. 270–277, 2019.
[9] J. Wang et al., “Landscape of DILI-related adverse drug reaction in China Mainland,” Acta Pharm. Sin. B, vol. 12, no. 12, pp. 4424–4431, 2022.
[10] B. R. Del Pozzo‐Magaña and C. Liy‐Wong, “Drugs and the skin: A concise review of cutaneous adverse drug reactions,” Br. J. Clin. Pharmacol., vol. 90, no. 8, pp. 1838–1855, 2024.
[11] P. Das and D. H. Mazumder, “MLCNNF: A Multi-Label Convolutional Neural Network Framework for Predicting Adverse COVID Drug Reactions From the Chemical Structure,” IEEE Trans. Comput. Biol. Bioinf., 2025.
[12] Y. Zhuang, J. Zhang, R. Lu, K. He, and X. Li, “MedNER: Enhanced Named Entity Recognition in Medical Corpus via Optimized Balanced and Deep Active Learning,” ACM Trans. Intell. Syst. Technol., vol. 15, no. 5, pp. 1–24, 2024.
[13] S. Jung and S. Yoo, “Interpretable prediction of drug-drug interactions via text embedding in biomedical literature,” Comput. Biol. Med., vol. 185, p. 109496, 2025.
[14] G. Geng et al., “MGDDI: A multi-scale graph neural networks for drug–drug interaction prediction,” Methods, vol. 228, pp. 22–29, 2024.
[15] A. Osheba et al., “Leveraging Large Language Models for Smart Pharmacy Systems: Enhancing Drug Safety and Operational Efficiency,” in Proc. 19th Int. Conf. Ubiquitous Inf. Manag. Commun. (IMCOM), Jan. 2025, pp. 1–8.
[16] W. Xie et al., “Transformer-based Named Entity Recognition for Clinical Cancer Drug Toxicity by Positive-unlabeled Learning and KL Regularizers,” Curr. Bioinform., vol. 19, no. 8, pp. 738–751, 2024.
[17] L. Sun, Z. Yin, and L. Lu, “ISLRWR: A network diffusion algorithm for drug–target interactions prediction,” PLoS One, vol. 20, no. 1, p. e0302281, 2025.
[18] Y. Cao, W. Wang, and Y. He, “Prediction of Heat-Treated Wood Adhesive Strength Using BP Neural Networks Optimized by Four Novel Metaheuristic Algorithms,” Forests, vol. 16, no. 2, p. 291, 2025.
[19] D. Azzalini et al., “An empirical evaluation of deep autoencoders for anomaly detection in the electricity consumption of buildings,” Energy Build., vol. 327, p. 115069, 2025.
[20] M. Issa, M. A. Elaziz, and S. I. Selem, “Enhanced hunger games search algorithm that incorporates the marine predator optimization algorithm for optimal extraction of parameters in PEM fuel cells,” Sci. Rep., vol. 15, no. 1, p. 4474, 2025.
[21] “ADHD diagnosis data,” Kaggle, 2021. [Online]. Available: https://www.kaggle.com/datasets/arashnic/adhd-diagnosis-data.
[22] J. Wei, Z. Lu, K. Qiu, P. Li, and H. Sun, “Predicting drug risk level from adverse drug reactions using SMOTE and machine learning approaches,” IEEE Access, vol. 8, pp. 185761–185775, 2020.
[23] A. Rawat et al., “Drug adverse event detection using text-based convolutional neural networks (TextCNN) technique,” Electronics, vol. 11, no. 20, p. 3336, 2022.
[24] J. Yang, Z. Hu, L. Zhang, and B. Peng, “Predicting Drugs Suspected of Causing Adverse Drug Reactions Using Graph Features and Attention Mechanisms,” Pharmaceuticals, vol. 17, no. 7, p. 822, 2024.
Cite This Article
Choose your preferred format